Greenland Mines Ltd (GRML): Total Liabilities
$129.8K
As of 2025-12-31
$7.11M
As of 2026-06-30
-70.3%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $129.8K | -89.8% | 2026-08-14, Balance as of period end |
| 2024-12-31 | $1.27M | -21.5% | 2026-08-14, Balance as of period end |
| 2023-12-31 | $1.62M | -67.1% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $4.93M | n/m | 2024-04-17, Balance as of period end |
| 2021-12-31 | $8.5K | n/a | 2023-10-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | 2025-12-31 | $129.8K | -89.8% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
| Calidi Biotherapeutics, Inc. (CLDI) | 2025-12-31 | $5.10M | -58.3% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $284.9K | -13.1% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $8.48M | +104.1% |
| Silexion Therapeutics Corp (SLXN) | 2025-12-31 | $4.61M | -32.7% |
| BioAtla, Inc. (BCAB) | 2025-12-31 | $50.02M | +31.1% |
| Intensity Therapeutics, Inc. (INTS) | 2025-12-31 | $2.23M | +19.3% |
| Exozymes Inc. (EXOZ) | 2025-12-31 | $2.57M | -1.5% |
Compare GRML, DYAI, CLDI, CELZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗